Microvascular Disease Exercise Trial (MOVE)
Assessment of Perfusion Reserve and Effects of Exercise in Microvascular Angina
Sponsor: Astellas Pharma Global Development, Inc.
Listed as NCT02045459, this NA trial focuses on Coronary Microvascular Disease and remains completed. Sponsored by Astellas Pharma Global Development, Inc., it has been updated 6 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Global Development, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .